Latest
Cardiac T2* Magnetic Resonance Imaging of Siderosis Validated in Patients With Thalassemia Major
COVID-19 Vaccines May Give Protection for Years: Studies
Ivosidenib Plus Venetoclax, With or Without Azacitidine, Appears Effective in IDH1-Mutated Myeloid Malignancies
Iberdomide-Based Regimens Show Promise in Relapsed/Refractory Multiple Myeloma
Long-Term Follow-Up Data Support Adding Daratumumab to Lenalidomide/Dexamethasone in Transplant-Ineligible MM
Continued Benefit Observed With Isatuximab Plus Pomalidomide and Dexamethasone in Multiple Myeloma
Leukemia-Specific T-cells Promising for Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Positive Outcomes Seen With an Exercise Program for Patients With Sickle Cell Disease
Preeclampsia May Be a Risk Factor for Later-Life Stroke
NSAID Use Not Linked to Increased Mortality, Severity in COVID-19
Relapsed, Refractory Follicular Lymphoma: CAR-T Cell Therapy Shows Promise
DLBCL: Naratuximab Shows Promise Among Patients With Relapsed/Refractory Disease
Featured Content
-
ASCO 2021 Coverage
Coverage from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. -
Treatment Challenges in Mild-To-Moderate Hemophilia
Researchers worked to better understand and manage patients with mild or moderate hemophilia, who can be an underrepresented and underserved population. -
Current State of Combination Therapy for Checkpoint Inhibitors
Despite the clinical success of combination therapy with immune checkpoint inhibitors many research questions still remain. -
NCCN Guidelines for Multiple Myeloma Updated to Include Three Selinexor Regimens
The National Comprehensive Cancer Network’s updated Clinical Practice Guidelines in Oncology for multiple myeloma newly include 3 new selinexor-containing regimens. -
Telemedicine for Hematology During COVID-19 and Beyond
The benefits of telemedicine became more evident in the context of the elevated risk of COVID-19 infection and severe symptoms among the patients served by hematology and oncology practices. -
Mild to Moderate Hemophilia: Experts Discuss Challenges and Propose Solutions
A group of US-based hemophilia experts summarized unmet needs in mild to moderate hemophilia and provided suggestions for healthcare professionals to optimally manage their patients with this challenging condition. -
American Society of Hematology Releases Updated Guidelines for Treating Newly Diagnosed AML in Older Adults
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
- Loading...
Loading...
Loading... 
Loading...